---
title: "Pre-market hot trades in US stocks: ARB IOT pre-market up 43.84%; Platinum Analytics Cayman - CL pre-market up 40.11%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/258298272.md"
description: "ARB IOT pre-market up 43.84%; Platinum Analytics Cayman - CL pre-market up 40.11%; Qualigen Therapeutics pre-market up 141.90%; Metsera pre-market up 56.81%; Agriforce Growing pre-market up 53.94%"
datetime: "2025-09-22T08:01:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/258298272.md)
  - [en](https://longbridge.com/en/news/258298272.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/258298272.md)
---

# Pre-market hot trades in US stocks: ARB IOT pre-market up 43.84%; Platinum Analytics Cayman - CL pre-market up 40.11%

**Popular Pre-Market Trades in U.S. Stocks**

**Top Gainers in U.S. Pre-Market Trading**

Qualigen Therapeutics is up 141.90% in pre-market trading. According to recent important news:

1.  On September 20, Faraday Future announced a strategic investment of $41 million in Qualigen Therapeutics to promote its cryptocurrency and Web3 business development. This news led to a significant increase in QLGN's stock price. Source: IT Home.
    
2.  On September 22, Qualigen Therapeutics announced it would change its name to CXC10, focusing on cryptocurrency business and Web3 ecosystem development, further boosting market confidence. Source: IT Home.
    
3.  On September 19, Faraday Future and Qualigen Therapeutics reached a PIPE agreement, with Faraday Future set to hold over 62% of QLGN shares, enhancing investor confidence in the company's future development. Source: Reuters. The trends in the cryptocurrency and Web3 industry are positive.
    

Metsera is up 56.81% in pre-market trading. Based on recent important news:

1.  On September 22, Pfizer announced it would acquire the biotechnology company Metsera for $47.50 per share in cash, with potential additional payments of $22.50 per share based on performance milestones, bringing the total valuation of Metsera to as much as $7.3 billion. This news propelled Metsera's stock price up 56.81% in pre-market trading. The obesity drug market is rapidly developing, and Pfizer's acquisition of Metsera

### Related Stocks

- [ARBB.US](https://longbridge.com/en/quote/ARBB.US.md)
- [PLTS.US](https://longbridge.com/en/quote/PLTS.US.md)

## Related News & Research

- [Sylvania Platinum Tightens Capital Base with Latest Share Buyback](https://longbridge.com/en/news/281474210.md)
- [Maxim Group Sticks to Its Buy Rating for ARB IOT Group Limited (ARBB)](https://longbridge.com/en/news/270317073.md)
- [Arbuthnot Banking Group (LON:ARBB) Hits New 52-Week High  - Time to Buy?](https://longbridge.com/en/news/272995557.md)